NovaSterilis
3109 N. Triphammer Road
Lansing, NY 14882
607.330.2772
novasterilis.com

Press Release

NovaSterilis to Present Phase 1 Data on Sterilization of Absorbable Polymers at Medtech Polymers Conference September 12

Lansing, NY; September 10, 2012 – NovaSterilis Inc, a leader in the development and commercialization of supercritical CO_2 applications will present data from a phase l NIH grant validating the sterilization of absorbable sutures utilizing their patented process. Thomas Steffie, Vice President of Business Development, will present these data at Medtech Polymers Conference 2012 in Chicago IL (September 11-12) highlighting the benefits of this green technology for sterilization on absorbable polymers.

"This is a fantastic opportunity to showcase NovaSterilis technology and our ability to overcome obstacles to thought leaders in the development of medical polymers", stated Mr. Steffie. "The attendees at this meeting are developing the next generation of materials that will impact the medical device, regenerative medicine and pharmaceutical industries and ultimately will improve patient safety and clinical outcomes."

NovaSterilis supercritical CO_2 sterilization technology achieves a Sterility Assurance Level of 10^{-6} (SAL6) or a one in a million chance of a contaminated item. This process achieves this high level of sterilization without significantly affecting many delicate materials and without the toxic residual chemicals of other processes. It is the ideal technology for many implantable devices and provides medical material companies an environmentally friendly alternative sterilization technology.

Supercritical CO_2 sterilization is currently being used by tissue banks to sterilize allograft tissue for transplantation. In addition, multiple device companies are developing products using this same technology. Allograft tissue has historically presented challenges to sterilization because radiation, heat and steam affect the strength and mechanical properties of the graft and chemical processes, for example ethylene oxide, leaves unacceptable levels of chemical residuals. The NovaSterilis process has proven very effective and safe for allograft tissue and physicians have expressed positive feedback on the final tissue products. Absorbable polymers present similar issues and NovaSterilis is confident that they can overcome processing issues by refining the process to meet the specific needs of a product, which is exactly what our team did with the suture grant.

To learn more about NovaSterilis or supercritical CO2 sterilization please visit or request additional information at www.novasterili.com.